1887

Chapter 7 : Manipulation of the Humoral Immune System and the Host Immune Response to Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Manipulation of the Humoral Immune System and the Host Immune Response to Infection, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818043/9781555811679_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555818043/9781555811679_Chap07-2.gif

Abstract:

The humoral immune system comprises elements that, in part, provide protection against invading organisms. This chapter discusses the effects of manipulating the humoral immune system on the risk of developing microbial infections. Plasmapheresis (also called plasma exchange) has been utilized as a therapy for a limited number of immunological diseases that are caused by autoantibodies. Plasmapheresis has several possible benefits. First, plasma exchange may remove a portion of pathogenic autoantibodies. Second, removal of some circulating immune complexes may be achieved by plasmapheresis, although it has almost no effect on tissue-bound immune complexes that may be formed in situ. Specific methods, such as specific immunoadsorption methods, have been developed to remove specific pathogenic antibodies. Immunoadsorbents have been developed that remove immunoglobulins nonspecifically or that remove specific antibodies selectively. Elements of innate immunity such as natural antibodies and complement have clearly been shown to play an important role in host resistance against microorganisms. Experimental and clinical studies are needed to fully appreciate the beneficial and harmful effects of methods that interfere with unwanted pathologic effects of elements of the humoral immune system.

Citation: Wagner E, Frank M. 2001. Manipulation of the Humoral Immune System and the Host Immune Response to Infection, p 139-157. In Platt J (ed), Xenotransplantation. ASM Press, Washington, DC. doi: 10.1128/9781555818043.ch7

Key Concept Ranking

Complement Receptor Type 1
0.5007874
Complement System
0.49293524
Immune Systems
0.41502506
0.5007874
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Pathways of complement activation. Activators of complement such as microorganisms and antigen-antibody complexes bind the first component of each pathway to initiate activation of the entire cascade. Reactions beyond C3 activation are common to all three pathways and result in the formation of the C5-9 complex known as the membrane attack complex. C, complement component; MBL, mannan-binding lectin; MASP, mannan-binding lectin-associated serine protease; C3(H2O), C3 that underwent spontaneous hydrolysis of its thiolester group; B, factor B; D, factor D; P, properdin.

Citation: Wagner E, Frank M. 2001. Manipulation of the Humoral Immune System and the Host Immune Response to Infection, p 139-157. In Platt J (ed), Xenotransplantation. ASM Press, Washington, DC. doi: 10.1128/9781555818043.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818043.chap7
1. Ahlstedt, S. 1981. Experimental Escherichia coli 06 infection in mice. Acta Pathol. Microbiol. Scand. 89( C): 23 28.
2. Alarabi, A. A.,, B. Nilsson,, U. Nilsson,, B. Wikstrom,, and B. G. Danielson. 1993. Complement activation during tryptophan immunoadsorption treatment. Artif. Organs 17: 782 786.
3. Alarabi, A.,, U. Backman,, O. Wikstrom Sjoberg,, and G. Tufveson. 1997. Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Int. J. Artif. Organs 20: 51 56.
4. Aoki, T.,, M. J. Walling,, G. S. Bushar,, M. Liu,, and K. C. Hsu. 1976. Natural antibodies in sera from healthy humans to antigens on surfaces of type C RNS viruses and cells from primates. Proc. Natl. Acad. Sci. USA 73: 2491 2495.
5. Aringer, M.,, J. S. Smolen,, and W. B. Graninger. 1998. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum. 41: 414 420.
6. Avrameas, S. 1991. Natural antibodies: from "horror autotoxicus" to "gnothi seauton." Immunol. Today 12: 154 159.
7. Basta, M. 1996. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin. Exp. Immunol. 104( Suppl. l): 21 25.
8. Basta, M.,, and M. C. Dalakas. 1994. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94: 1729 1735.
9. Basta, M.,, P. Kirshbom,, M. M. Frank,, and L. F. Fries. 1989. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 84: 1974 1981.
10. Beebe, D. P.,, and N. R. Cooper. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126: 1562 1568.
11. Berglin, E.,, C. Kjellstrom,, V. Mantovani,, G. Stelin,, C. Svalander,, and L. Wiklund. 1995. Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Transplant Int. 8: 382 387.
12. Bitter-Suermann, D.,, and R. Burger. 1986. Guinea pigs deficient in C2, C4, C3 or the C3a receptor. Prog. Allergy 39: 134 158.
13. Boyden, S. 1964. Natural antibodies and the immune response. Adv. Immunol. 5: 1 28.
14. Brauer, R. B.,, W. M. Baldwin III,, S. Ibrahim,, and F. Sanfilippo. 1995. The contribution of the terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 59: 288 293.
15. Briles, D.,, M. Nahm,, K. Schroer,, J. Davie,, P. Baker,, J. Kearney,, and R. Barlettas. 1981. Antiphospho-choline antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153: 694 705.
16. Brown, E. J.,, M. Berger,, K. A. Joiner,, and M. M. Frank. 1983. Classical pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect. Immun. 42: 594 598.
17. Brown, E. J.,, S. W. Hosea,, and M. M. Frank. 1981. Reticuloendothelial clearance of radiolabeled pneumococci in experimental bacteremia: correlation of changes in clearance rates, sequestration patterns, and opsonization requirements at different phases of the bacterial growth cycle. J. Reticuloendothelial Soc. 30: 23 31.
18. Brown, E. J.,, S. W. Hosea,, and M. M. Frank. 1981. The role of the spleen in experimental pneumococcalbacteremia. J. Clin. Invest. 67: 975 982.
19. Brown, E. J.,, S. W. Hosea,, C. H. Hammer,, C. G. Burch,, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Invest. 69: 85 98.
20. Budzko, D. B.,, M. C. Pizzimenti,, and F. Kierszenbaum. 1975. Effects of complement depletion in ex-perimental Chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi. Infect. Immun. 11: 86 91.
21. Buerke, M.,, T. Morohara,, and A. M. Lefer. 1995. Cardioprotective effects of a CI esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393 402.
22. Candinas, D.,, B.-A. Lesnikoski,, S. C. Robson,, T. Miyatake,, S. M. Scesney,, H. C. Marsh, Jr.,, U. S. Ryan,, A. P. Dalmasso,, W. W. Hancock,, and F. H. Bach. 1996. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 62: 336 342.
23. Casali, P.,, and A. L. Notkins. 1989. CD5+ B lymphocytes, polyreactive antibodies and the human B cell repertoire. Immunol. Today 10: 364 368.
24. Casali, P.,, and E. W. Schettino. 1996. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210: 167 179.
25. Challacombe, S. J.,, L. A. Bergmeier,, C. Czerkinsky,, and A. S. Rees. 1984. Natural antibodies in man to Streptococcus mutans: specificity and quantification. Immunology 52: 143 150.
26. Chopek, M.,, and J. McCulIogh,. 1980. Protein and biochemical changes during plasma exchange, p. 13 52. In J. Ulmas, and B. Berkman (ed.), Therapeutic Haemapheresis: A Technical Workshop. American Association of Blood Banks, Washington, D.C.
27. Cooper, N. R., 1998. Complement and viruses, p. 393 407. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.
28. Dalmasso, A. P. 1992. The complement system in xenotransplantation. Immunopharmacology 24: 149 160.
29. Dalmasso, A. P.,, and J. L. Platt 1993. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by CI inhibitor. Transplantation 56: 1171 1176.
30. Dalmasso, A. P.,, G. M. Vercellotti,, R. J. Fischel,, R. M. Bolman,, F. H. Bach,, and J. L. Platt. 1992. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am. J. Pathol. 140: 1157 1166.
31. Davis, E. A.,, S. K. Pruitt,, P. S. Greene,, S. Ibrahim,, T. T. Lam,, J. L. Levin,, W. M. Baldwin D3,, and F. Sanfllippo. 1996. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 62: 1018 1023.
32. Densen, P., 1998. Complement deficiencies and infection, p. 409 421. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.
33. Dwyer, J. M. 1992. Manipulating the immune system with immune globulin. N. Engl. J. Med. 326: 107 116.
34. Epstein, J.,, Q. Eichbaum,, S. Sheriff,, and R. A. B. Ezekowitz. 1996. The collectins in innate immunity. Curr. Opin. Immunol. 8: 29 35.
35. Evans, M. J.,, S. A. Rollins,, D. W. Wolff,, R. P. Rother,, A. J. Norin,, D. M. Therrien,, G. A. Grijalva,, J. P. Mueller,, S. H. Nye,, S. P. Squinto,, and J. A. Wilkins. 1995. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol. Immunol. 32: 1183 1195.
36. Farges, O.,, A. N. Kalil,, D. Samuel,, F. Saliba,, J. L. Arulnaden,, P. Debat,, A. Bismuth,, D. Castaing,, and H. Bismuth. 1995. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 59: 1124 1133.
37. Fearon, D. T. 1984. Cellular receptors for fragments of the third component of complement. Immunol. Today 5: 105 110.
38. Figueroa, J. E.,, and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4: 359 395.
39. Fishelson, Z. 1994. Complement-related proteins in pathogenic organisms. Springer Semin. Immunopathol. 15: 345 368.
40. Fisher, M. B.,, A. P. Prodeus,, A. Nicholson-Weller,, M. Ma,, J. Murrow,, R. R. Reid,, H. B. Warren,, L. Lage,, F. D. Moore, Jr.,, F. S. Rosen,, and M. C. Carroll. 1997. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159: 976 982.
41. Frank, M. M. 1995. Animal models for complement deficiencies. J. Clin. Immunol. 15: 113S 121S.
42. Frank, M. M.,, and L. F. Fries,. 1989. Complement, p. 679 701. In W. E. Paul (ed.), Fundamental Immunology, 2nd ed. Raven Press, Ltd., New York, N.Y.
43. Frank, M. M.,, and L. F. Fries. 1998. The role of complement in defence against bacterial disease. Bailliere's Clin. Immunol. Allergy 2: 335 361.
44. Frank, M. M.,, K. A. Joiner,, and C. H. Hammer. 1987. The function of antibody and complement in thelysis of bacteria. Rev. Infect. Dis. 9: S537 S545.
45. Galili, U. 1993. Evolution and pathophysiology of the human natural anti-galactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15: 155 171.
46. Goes, A. M.,, and F. J. Ramalho-Pinto. 1991. Protective immunity to Schistosoma mansoni in mice is dependent on antibody and complement but not on radiosensitive leukocytes. Immunol. Lett. 28: 57 64.
47. Griffin, S. V.,, C. M. Lockwood,, and C. D. Pusey,. 1996. Plasmapheresis and immunoadsorption, p. 636 651. In K. F. Austen,, S. J. Burakoff,, F. S. Rosen,, and T. B. Strom (ed.), Therapeutic Immunology. Blackwell Science, Inc., Cambridge, Mass.
48. Harindranath, N.,, H. Ikematsu,, A. L. Notkins,, and P. Casali. 1993. Structure of the V H and V L segments of polyreactive and monoreactive human natural antibodies to HIV-1 and Escherichia coli β-galactosidase. Int. Immunol. 5: 1523 1533.
49. Higgins, R. M.,, D. J. Bevan,, B. S. Carey,, C. K. Lea,, M. Fallon,, R. Buhler,, R. W. Vaughan,, P. J. O'Donnell,, S. A. Snowden,, M. Bewick,, and B. M. Hendry. 1996. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 348: 1208 1211.
50. Hirsh, R. L.,, D. E. Griffin,, and J. A. Winkelstein. 1978. The effect of complement depletion on the course of sindbis virus infection in mice. J. Immunol. 121: 1276 1278.
51. Horowitz, J.,, J. E. Volanakis,, and D. E. Briles. 1987. Blood clearance of Streptococcus pneumoniae by C-reactive protein. J. Immunol. 138: 2598 2603.
52. Ishiwaka, A.,, M. Itoh,, T. Ushlyama,, K. Suzuki,, and K. Fujita. 1998. Experience of ABO-incompatible living kidney transplantation after double filtration plasmapheresis. Clin. Transplant. 12: 80 83.
53. Jakobs, F. M.,, E. A. Davis,, T. White,, F. Sanfilippo,, and W. M. Baldwin III. 1998. Prolonged discordant xenograft survival by inhibition of the intrinsic coagulation pathway in complement C6-deficient recipients. J. Heart Lung Transplant. 17: 306 311.
54. Kalli, K. R.,, P. Hsu,, and D. T. Fearon. 1994. Therapeutic uses of recombinant complement protein inhibitors. Semin. Immunopathol. 15: 417 431.
55. Kantor, A. B. 1991. The development and repertoire of B-l cells (CD5 B cells). Immunol. Today 12: 389 391.
56. Kaplan, M. H.,, and J. E. Volanakis. 1974. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J. Immunol. 112: 2135 2147.
57. Kearns-Jonker, M.,, M. Fraiman,, W. Chu,, E. Gochi,, J. Michel,, G.-D. Wu,, and D. V. Cramer. 1998. Xenoantibodies to pig endothelium are expressed in germline configuration and share a conserved immunoglobulin V H gene structure with antibodies to common infectious agents. Transplantation 5: 1515 1519.
58. Kemp, E. 1996. Xenotransplantation. J. Intern. Med. 239: 287 297.
59. Kirschfink, M. 1997. Controlling the complement system in inflammation. Immunopharmacology 38: 51 62.
60. Klickstein, L. B.,, T. J. Bartow,, V. Miletic,, L. D. Rabson,, J. A. Smith,, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168: 1699 1717.
61. Konishi, E.,, and M. Nakao. 1992. Naturally occurring immunoglobulin M antibodies: enhancement of phagocytic and microbicidal activities of human neutrophils against Toxoplasma gondii. Parasitology 104: 427 432.
62. Kozel, T. R. 1996. Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev. 9: 34 46.
63. Kroshus, T. J.,, S. A. Rollins,, A. P. Dalmasso,, E. A. Elliott,, L. A. Matis,, S. P. Squinto,, and R. M. Bolman HI. 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60: 1194 1202.
64. Leventhal, J. R.,, A. P. Dalmasso,, J. W. Cromwell,, J. L. Platt,, C. J. Manivel,, R. M. Bolman HI,, and A. J. Matas. 1993. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55: 857 866.
65. Leventhal, J. R.,, R. John,, J. P. Fryer,, J. C. Witson,, J.-M. Derlich,, J. Remiszewski,, A. P. Dalmasso,, A. J. Matas,, and R. M. Bolman III. 1995. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation 59: 294 300.
66. Leventhal, R.,, H. Bonner,, E. J. L. Soulsby,, and A. D. Schreiber. 1978. The role of complement in Ascaris suum induced histopathology. Clin. Exp. Immunol. 32: 69 76.
67. Lin, S. S.,, D. L. Kooyman,, L. J. Daniels,, C. W. Daggett,, W. Parker,, J. H. Lawson,, C. W. Hoopes,, C. Gullotto,, L. Li,, P. Birch,, R. D. Davis,, L. E. Diamond,, J. S. Logan,, and J. L. Platt. 1997. The role of natural anti-gala l-3gal antibodies in hyperacute rejection of pig-to-baboon cardiac transplants. Transplant. Immunol. 5: 212 218.
68. Lutz, H. U.,, P. Stanunler,, E. Jelezarova,, M. Nater,, and P. J. Spath. 1996. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in (C3b)n-IgG complexes. Blood 88: 184 193.
69. Lydyard, P. M.,, A. Lamour,, L. E. MacKenzie,, C. Jamin,, R. A. Mageed,, and P. Youinou. 1993. CD5+ B cells and the immune system. Immunol. Lett. 38: 159 166.
70. Magee, J. C.,, B. H. Collins,, R. C. Harland,, B. J. Lindman,, R. R. Bollinger,, M. M. Frank,, and J. L. Platt 1995. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J. Clin. Invest. 96: 2404 2412.
71. Makrides, S. C. 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50: 59 87.
72. Marsh, J. E.,, M. C. Carroll,, and S. H. Sacks. 1998. The classic pathway augments production of alloantibodies. Mol. Immunol. 35: 393.
73. Matsushita, M.,, and T. Fujita. 1996. The lectin pathway. Res. Immunol. 147: 115 118.
74. May, J. E.,, M. A. Kane,, and M. M. Frank. 1972. Host defense against bacterial endotoxemia. Contribution of the early and late components of complement to detoxification. J. Immunol. 109: 893 895.
75. Michael, J. G. 1969. Natural antibodies. Curr. Top. Microbiol. Immunol. 48: 43 62.
76. Miletic, V. D.,, C. G. Hester,, and M. M. Frank. 1996. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J. Immunol. 156: 749 757.
77. Miller, T. E.,, S. Phillips,, and T. J. Simpson. 1978. Complement-mediated immune mechanisms in renal infection, n. Effect of decomplementation. Clin. Exp. Immunol. 33: 115 121.
78. Miyagawa, S.,, R. Shirakura,, G. Matsumiya,, N. Fukushima,, S. Nakata,, H. Matsuda,, M. Matsumoto,, H. Kitamura,, and T. Seya. 1993. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT-175. Transplantation 55: 709 713.
79. Mokrzycki, M. H.,, and A. A. Kaplan. 1994. Therapeutic plasma exchange: complications and management. Am. J. Kidney Dis. 23: 817 827.
80. Mollnes, T. E.,, K. Hogasen,, B. F. Hoaas,, T. E. Michaelsen,, P. Garred,, and M. Harboe. 1995. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding preperties. Scand. J. Immunol. 41: 449 456.
81. Moore, F. D., Jr.,, D. T. Fearon,, and K. F. Austen. 1981. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J. Immunol. 126: 1805 1809.
82. Mor, E.,, D. Skerrett,, C. Manzarbeitia,, P. A. Sheiner,, M. E. Schwartz,, S. Emre,, S. N. Thung,, and C. M. Miller. 1995. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 59: 986 990.
83. Morgan, B. P. 1995. Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32: 265 298.
84. Morgan, B. P.,, and S. Meri. 1994. Membrane proteins that protect against complement lysis. Semin. Immunopathol. 15: 369 396.
85. Mouthon, L.,, S. V. Kaveri,, S. H. Spalter,, S. Lacroix-Desmazes,, C. Lefranc,, R. Desai,, and M. D. Kazatchkine. 1996. Mechanism of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104( Suppl. l): 3 9.
86. Naik, R. B.,, R. Ashlin,, C. Wilson,, D. S. Smith,, H. A. Lee,, and M. Slapak. 1979. The role of plasmapheresis in renal transplantation. Clin. Nephrol. 11: 245 250.
87. Norrgren, K.,, S. E. Strand,, and C. Ingvar. 1992. Contrast enhancement in RII and modification of the therapeutic ratio in RIT: a theoretical evaluation of simulated extracorporeal immunoadsorption. Antibody Immunoconj. Radiopharmaceut. 5: 61 73.
88. Ohta, H.,, Y. Yoshikawa,, C. Kai,, K. Yamanouchi,, H. Taniguchi,, K.-I. Komine,, Y. Ishijima,, and H. Okada. 1986. Effect of complement depletion by cobra venom factor on fowlpox virus infection in chickens and chicken embryos. J. Virol. 57: 670 673.
89. Olivari, M.-T.,, C. B. May,, N. A. Johnson,, W. S. Ring,, and M. K. Stephens. 1994. Treatment of acute vascular rejection with immunoadsorption. Circulation 90: 1170 1173.
90. Olsen, S. L.,, L. E. Wagoner,, E. H. Hammond,, D. O. Taylor,, R. L. Yowell,, R. D. Ensley,, M. R. Bristow,, J. B. O'Connell,, and D. G. Renlund. 1993. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J. Heart Lung Transplant. 12: S135 S142.
91. Pangburn, M. K.,, and H. J. Müller-Eberhard. 1984. The alternative pathway of complement. Semin. Immunopathol. 7: 163 192.
92. Parker, W.,, D. Bruno,, and J. L. Platt. 1995. Xenoreactive antibodies in the world of natural antibodies: typical or unique? Transplant. Immunol. 3: 181 191.
93. Petry, F.,, and M. Loos,. 1998. Bacteria and complement, p. 375 391. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.
94. Platt, J. L., 1995. Natural antibodies, p. 55 80. In J. L. Platt (ed.), Hyperacute Xenograft Rejection. R.G. Landes Co., Georgetown, Tex.
95. Platt, J. L. 1998. New directions for organ transplantation. Nature 392: 11 17.
96. Platt, J. L.,, S. S. Lin,, and C. G. A. McGregor. 1998. Acute vascular rejection. Xenotransplantation 5: 169 175.
97. Pohl, M. A.,, S.-P. Lan,, T. Berl, and the Lupus Nephritis Collaborative Study Group. 1991. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann. Intern. Med. 114: 924 929.
98. Poulle, M.,, M. Burnouf-Radosevich,, and T. Burnouf. 1994. Large-scale preparation of highly purified human CI inhibitor for therapeutic use. Blood Coagul. Fibrinolysis 5: 543 549.
99. Pratt, J. R.,, A. W. Harmer,, J. Levin,, and S. H. Sacks. 1997. Influence of complement on the allospecific antibody response to a primary vascularized organ graft. Eur. J. Immunol. 27: 2848 2853.
100. Pratt, J. R.,, M. J. Hibbs,, A. J. Laver,, A. G. Smith,, and S. H. Sacks. 1996. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol. 149: 2055 2066.
101. Pretagostini, R.,, P. Berloco,, L. Poli,, P. Cinti,, A. Di Nicuolo,, P. De Simone,, M. Colonnello,, A. Salerno,, D. Alfani,, and R. Cortesini. 1996. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J. 42: M645 M648.
102. Pruitt, S. K.,, A. D. Kirk,, R. R. Bollinger,, H. C. Marsh, Jr.,, B. H. Collins,, J. L. Levin,, J. R. Mault,, J. S. Heinle,, S. Ibrahim,, A. R. Rudolph,, V. M. Baldwin III,, and F. Sanfllippo. 1994. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363 370.
103. Qi, M.,, and J. A. Shifferli. 1995. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum. 38: 146.
104. Qian, Z.,, F. M. Jakobs,, T. Pfaff-Amesse,, F. Sanfllippo,, and W. M. Baldwin III. 1998. Complement contributes to the rejection of complete and class I major histocompatibility complex-incompatible cardiac allografts. J. Heart Lung Transplant. 17: 470 478.
105. Reid, R. R.,, A. P. Prodeus,, W. Khan,, T. Hsu,, F. S. Rosen,, and M. C. Carroll. 1997. Endotoxin shock in antibody-deficient mice. Unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159: 970 975.
106. Ritter, K.,, A. Fudickar,, N. Heine,, and R. Thomssen. 1997. Autoantibodies with a protective function: polyreactive antibodies against alkaline phosphatase in bacterial infections. Med. Microbiol. Immunol. 186: 109 113.
107. Rodman, T. C.,, S. E. To,, J. J. Sullivan,, and R. Winston. 1997. Innate natural antibodies. Primary roles indicated by specific epitopes. Hum. Immunol. 55: 87 95.
108. Rollins, S. A.,, J. C. K. Fitch,, S. Sherman,, C. S. Rinder,, H. M. Rinder,, B. R. Smith,, C. D. Collard,, G. L. Stahl,, B. L. Alford,, L. Li,, and L. A. Matis. 1998. Anti-C5 single chain antibody therapy blocks complement and leukocyte activation and reduces myocardial tissue damage in CPB patients. Mol. Immunol. 35: 397.
109. Rollins, S. A.,, L. A. Matis,, J. P. Springhorn,, E. Setter,, and D. W. Wolff. 1995. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 60: 1284 1292.
110. Saadi, S.,, and J. L. Platt 1998. Immunology of xenotransplantation. Life Sci. 62: 365 387.
111. Salmela, K. T.,, E. O. von Willebrand,, L. E. Kyllonen,, B. H. Eklund,, K. A. Hockerstedt,, H. M. Isoniemi,, L. Krogerus,, E. Taskinen,, and P. J. Ahonen. 1992. Acute vascular rejection in renal transplantation: diagnosis and outcome. Transplantation 54: 858 862.
112. Sanaka, T.,, S. Wakai,, S. Teraoka,, T. Takuma,, N. Sugino,, and T. Agishi,. 1990. Effect of therapeutic plasma exchange on immunological and renal pathological findings in patients with lupus nephritis, p. 351 353. In G. Rock (ed.), Apharesis. Alan R. Liss, Inc., New York, N.Y.
113. Sato, Y.,, M. Kimikawa,, H. Suga,, Y. Hayasaka,, S. Teraoka,, T. Agishi,, and K. Ota. 1992. Prolongation of cardiac xenograft survival by double filtration plasmapheresis and ex vivo immunoadsorption. ASAIO J. 38: M673 M675.
114. Schneider, K. M. 1998. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int. 53: S61 S65.
115. Schreiber, J. R.,, C. Basker,, and G. R. Siber. 1987. Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b. Infect. Immun. 55: 2830 2833.
116. Schweinle, J. E.,, R. A. B. Ezekowitz,, A. J. Tenner,, M. Kuhlman,, and K. A. Joiner. 1989. Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J. Clin. Invest. 84: 1821 1829.
117. Silverstein, A. M., 1993. The history of immunology, p. 21 41. In W. E. Paul (ed.), Fundamental Immunology, 3rd ed. Raven Press, Ltd., New York, N.Y.
118. Snyder, H. W.,, and E. Fleissner. 1980. Specificity of human antibodies to oncovirus glycoproteins: recognition of antigen by natural antibodies directed against carbohydrate structures. Proc. Natl. Acad. Sci. USA 77: 1622 1626.
119. Sonnenwirth, A. C. 1979. Antibody response to anaerobic bacteria. Rev. Infect. Dis. 1: 337 341.
120. Stegmayr, B. G. 1996. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 14: 94 101.
121. Stiehm, E. R.,, T. W. Chin,, A. Haas,, and A. G. Peerless. 1986. Infectious complications of the primary immunodeficiencies. Clin. Immunol. Immunopathol. 40: 69 86.
122. Strauss, R. G.,, D. Clavarella,, R. O. Gilcher,, D. O. Kasprisin,, D. D. Kiprov,, H. G. Klein,, and B. C. McLoed. 1993. An overview of current management. J. Clin. Apharesis 8: 189 194.
123. Suankratay, C.,, X.-H. Zhang,, Y. Zhang,, T. F. Lint,, and H. Gewurz. 1998. Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. J. Immunol. 160: 3006 3013.
124. Swift, A. J.,, T. S. Collins,, P. Bugelski,, and J. A. Winkelstein. 1994. Soluble complement receptor type 1 inhibits complement-mediated host defense. Clin. Diagn. Lab. Immunol. 1: 585 589.
125. Szalai, A. J.,, D. E. Briles,, and J. E. Volanakis. 1996. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect. Immun. 64: 4850 4853.
126. Tanaka, M.,, N. Murase,, Q. Ye,, W. Miyazaki,, M. Nomoto,, H. Miyazawa,, R. Manez,, Y. Toyama,, A. J. Demetris,, S. Todo,, and T. E. Starzl. 1996. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. Transplantation 62: 681 688.
127. Taniguchi, S.,, S. Kitamura,, K. Kawachi,, M. Fukutomi,, Y. Yoshida,, and Y. Kondo. 1992. Effects of double-filtration plasmapheresis and a platelet-activating factor antagonist on the prolongation of xenograft survival. J Heart Lung Transplant. 11: 1200 1208.
128. Thiel, S.,, T. Vorup-Jensen,, C. M. Stover,, W. Schwaeble,, S. B. Laursen,, K. Poulsen,, A. C. Willis,, P. Eggelton,, S. Hansen,, U. Holmskov,, K. B. M. Reid,, and J. C. Jensenius. 1997. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 606 610.
129. Thomas, T. C.,, S. A. Rollins,, R. P. Rother,, M. A. Giannoni,, S. L. Hartman,, E. A. Elliott,, S. H. Nye,, L. A. Matis,, S. P. Squinto,, and M. J. Evans. 1996. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33: 1389 1401.
130. TJlanova, M.,, M. Hahn-Zoric,, Y. L. Lau,, A. Lucas,, and L. A. Hanson. 1996. Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies. Clin. Exp. Immunol. 105: 422 428.
131. van Emmerik, L. C.,, E. J. Kuljper,, C. A. P. Fyen,, J. Dankert,, and S. Thiel. 1994. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin. Exp. Immunol. 97: 411 416.
132. Vogel, C. W.,, and H. J. Müller-Eberhard. 1982. The cobra venom factor-dependent C3 convertase of human complement. J. Biol. Chem. 257: 8292 8299.
133. Volanakis, J. E.,, and M. M. Frank (ed.). 1998. The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.
134. Wagner, E.,, and M. M. Frank,. 1998. Development of clinically useful agents to control complement-mediated tissue damage, p. 527 546. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.
135. Wagner, E.,, J. L. Platt,, and M. M. Frank. 1998. High dose intravenous immunoglobulin does not affect complement-bacteria interactions. J. Immunol. 160: 1936 1943.
136. Wang, Y.,, Q. L. Hu,, J. A. Madri,, S. A. Rollins,, A. Chodera,, and L. A. Matis. 1995. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93: 8563 8568.
137. Wang, Y.,, S. A. Rollins,, J. A. Madri,, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92: 8955 8959.
138. Waytes, A. T.,, F. S. Rosen,, and M. M. Frank. 1996. Treatment of angioedema with a vapor-heated CI inhibitor concentrate. N. Engl. J. Med. 334: 1630 1634.
139. Webster, A. D. B.,, G. P. Spickett,, B. J. Thompson,, and J. Farrant. 1988. Viruses and antibody deficiency syndromes. Immunol. Invest. 17: 93 105.
140. Weisman, H. E.,, T. Bartow,, M. K. Leppo,, H. C. Marsh, Jr.,, G. R. Carson,, M. F. Concino,, M. P. Boyle,, K. H. Roux,, M. L. Weisfeldt,, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146 151.
141. Wu, M. J.,, K. H. Shu,, C. H. Cheng,, and J. D. Lian. 1997. Complications of membrane-filtration plasma exchange. Chung Hual Shueh Chih (Taipei) 60: 147 154.
142. Zhang, W.,, and P. J. Lachman. 1994. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology 81: 137 141.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error